Generic Name: doravirine lamuvidine tenofovir disoproxil fumarate
Brand Name: TBC
Manufacturer: Merck Canada Inc.
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine, lamivudine, or tenofovir.
Submission Type: New Combination
Project Status: Pending
Call For Patient Input: September 14, 2018
Patient Input Closed: November 5, 2018
Anticipated Date: October 15, 2018
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.